GlassScriptPhysician profile
Annie Harris
NPI 1245872654
$2,145.31
in general payments reported to CMS, 2019-2025
32 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.42 · 2023: $244 · 2024: $808 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $197.99 | 2024-2025 | |
| Novocure INC. | $146.09 | 2022-2025 | Optune Lua (Novottf-200t) |
| Incyte Corporation | $137.39 | 2025 | Jakafi, Jakafi |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $122.56 | 2023-2025 | Erleada, Rybrevant, Talvey |
| Daiichi Sankyo INC. | $120.21 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $116.09 | 2024-2025 | |
| Gilead Sciences, INC. | $103.40 | 2024 | Trodelvy |
| Astellas Pharma US INC | $103.40 | 2025 | Vyloy |
| Regeneron Healthcare Solutions, INC. | $93.12 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $88.62 | 2025 | Calquence |
| Aveo Pharmaceuticals, INC. | $85.96 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.99 | 2023-2025 | Gilotrif, Jardiance |
| Tersera Therapeutics LLC | $64.19 | 2023-2025 | Zoladex, Xermelo |
| Adc Therapeutics America, INC. | $63.29 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $59.27 | 2024-2025 | Venclexta, Itovebi |
| Genzyme Corporation | $55.43 | 2024-2025 | |
| Taiho Oncology, INC. | $43.22 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.62 | 2023-2024 | |
| Eisai INC. | $39.42 | 2025 | |
| Abbvie INC. | $29.49 | 2024 | |
| Emd Serono, INC. | $25.10 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.91 | 2024 | Iclusig |
| Stemline Therapeutics INC. | $23.46 | 2024 | Orserdu |
| Xeris Pharmaceuticals, INC. | $22.82 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $22.52 | 2025 | Ojjaara |
| Celgene Corporation | $22.17 | 2024 | Pomalyst |
| Geron Corporation | $20.71 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $20.11 | 2024 | Qinlock |
| Rigel Pharmaceuticals, INC. | $19.47 | 2024 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $17.42 | 2023 | Monjuvi |
| Novo Nordisk INC | $15.87 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.